Meanwhile, Microchip Biotechnologies of Fremont, California ... Micronics Inc., Boehringer-Ingelheim's MicroParts, Silicon Valley Scientific Inc., Microdrop and LICOM (Box 2).

The state-of-the-art research and development center in Georgia will help improve the health and wellbeing of animals ...

The $66 million project is part of the company's obligation made to the state after it moved here to invest a total of $120 ...

Boehringer Ingelheim has halted development of an obesity drug from Gubra that it originally pledged to advance back in 2017, ...

With a capital investment of US$66.1 million and 63 new jobs created, this expansion includes the addition of 63,000 square feet of administrative space and more than 28,000 square feet of laboratory ...

Abdulla also aims to further strengthen relationships with regional governments and key healthcare stakeholders to ensure sustainable patient access to Boehringer Ingelheim’s portfolio of leading ...

Spending the day facing the challenges of kidney patients helps workers at a CT pharmaceutical company understand disease and ...

Notable Labs’ attempts to take a Boehringer Ingelheim cancer drug to market appear to have come to end with the oncology-focused platform company’s decision to file for bankruptcy. Notable's ...

Boehringer Ingelheim says it is on track to launch 25 new treatments in its human pharma division onto the market between now and 2030, fuelled by an R&D pipeline that it says is the best in its ...

Boehringer Ingelheim has taken an option on a family of compounds with potential as therapies for schizophrenia from Sosei Heptares, which it says could have broad activity against the symptoms of ...